GlassScriptPhysician profile
Brad David Vincent
NPI 1588747406
$12,073.54
in general payments reported to CMS, 2019-2025
30 companies · $1,704 in 2025
The $1,704 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2020: $699 · 2021: $365 · 2022: $991 · 2023: $278 · 2024: $7,313 · 2025: $1,704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,000 · Travel and Lodging: $1,161 · Food and Beverage: $934 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,000.00 |
| Travel and Lodging | $1,161.33 |
| Food and Beverage | $933.80 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,711.29 | 2019-2025 | Da Vinci Surgical System |
| Pulmonx Corporation | $616.86 | 2020-2024 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Glaxosmithkline, LLC. | $546.65 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.29 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $219.91 | 2022-2024 | |
| Paratek Pharmaceuticals, INC. | $147.39 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $143.02 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $136.84 | 2022-2024 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $127.16 | 2019-2023 | Breztri |
| Genzyme Corporation | $127.02 | 2021-2024 | |
| Grifols USA, LLC | $113.98 | 2020-2022 | |
| Mylan Specialty L.P. | $93.81 | 2022 | |
| La Jolla Pharmaceutical Company | $92.27 | 2019-2020 | |
| United Therapeutics Corporation | $88.86 | 2022-2025 | Tyvaso, Tyvaso |
| Viatris Specialty LLC | $85.90 | 2025 | Yupelri |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veran Medical Technologies, INC. | $83.10 | 2020 | |
| Merck Sharp & Dohme LLC | $78.85 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $56.69 | 2022 | |
| Portola Pharmaceuticals, LLC | $48.46 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $39.72 | 2022 | |
| Ucb, INC. | $36.75 | 2019 | |
| Chiesi USA, INC. | $34.11 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $25.62 | 2019 | |
| Advanced Respiratory, INC | $25.41 | 2020 | |
| Alexion Pharmaceuticals, INC. | $22.54 | 2022 | |
| Cardinal Health 200 LLC | $22.13 | 2021 | |
| Electromed, INC. | $21.84 | 2022 | |
| Insmed, INC. | $15.81 | 2019 | |
| Smith+Nephew, INC. | $15.45 | 2020 | |
| Pfizer INC. | $11.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Vincent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.